421 related articles for article (PubMed ID: 24742219)
1. MicroRNAs and drug resistance in prostate cancers.
Li F; Mahato RI
Mol Pharm; 2014 Aug; 11(8):2539-52. PubMed ID: 24742219
[TBL] [Abstract][Full Text] [Related]
2. Transcription factor and microRNA regulation in androgen-dependent and -independent prostate cancer cells.
Wang G; Wang Y; Feng W; Wang X; Yang JY; Zhao Y; Wang Y; Liu Y
BMC Genomics; 2008 Sep; 9 Suppl 2(Suppl 2):S22. PubMed ID: 18831788
[TBL] [Abstract][Full Text] [Related]
3. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
Begemann D; Anastos H; Kyprianou N
Int J Urol; 2018 Apr; 25(4):318-326. PubMed ID: 29345000
[TBL] [Abstract][Full Text] [Related]
4. Achieving resistance specificity in prostate cancer.
Wadhwa B; Dumbre R
Chem Biol Interact; 2016 Dec; 260():243-247. PubMed ID: 27720870
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance.
Ottman R; Nguyen C; Lorch R; Chakrabarti R
Mol Cancer; 2014 Jan; 13():1. PubMed ID: 24387052
[TBL] [Abstract][Full Text] [Related]
6. Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.
Singh S; Chitkara D; Mehrazin R; Behrman SW; Wake RW; Mahato RI
PLoS One; 2012; 7(6):e40021. PubMed ID: 22768203
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties.
Paranjape AN; Soundararajan R; Werden SJ; Joseph R; Taube JH; Liu H; Rodriguez-Canales J; Sphyris N; Wistuba I; Miura N; Dhillon J; Mahajan N; Mahajan K; Chang JT; Ittmann M; Maity SN; Logothetis C; Tang DG; Mani SA
Oncogene; 2016 Nov; 35(46):5963-5976. PubMed ID: 26804168
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression.
Huang S; Liu Q; Liao Q; Wu Q; Sun B; Yang Z; Hu X; Tan M; Li L
Cancer Sci; 2018 Mar; 109(3):678-687. PubMed ID: 29288516
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of a novel androgen receptor transgene responsive to MicroRNA mediated post-transcriptional control exerted via 3'-untranslated region.
Ebron JS; Shukla GC
Prostate; 2016 Jun; 76(9):834-44. PubMed ID: 26988939
[TBL] [Abstract][Full Text] [Related]
10. Role of MicroRNAs in Prostate Cancer Pathogenesis.
Wang YL; Wu S; Jiang B; Yin FF; Zheng SS; Hou SC
Clin Genitourin Cancer; 2015 Aug; 13(4):261-270. PubMed ID: 25733057
[TBL] [Abstract][Full Text] [Related]
11. Global gene expression analysis reveals reduced abundance of putative microRNA targets in human prostate tumours.
Sun R; Fu X; Li Y; Xie Y; Mao Y
BMC Genomics; 2009 Feb; 10():93. PubMed ID: 19245699
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.
Sun Y; Wang BE; Leong KG; Yue P; Li L; Jhunjhunwala S; Chen D; Seo K; Modrusan Z; Gao WQ; Settleman J; Johnson L
Cancer Res; 2012 Jan; 72(2):527-36. PubMed ID: 22108827
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer therapy outcome prediction: are miRNAs a suitable guide for therapeutic decisions?
Konoshenko M; Laktionov P; Bryzgunova O
Andrology; 2024 May; 12(4):705-718. PubMed ID: 37750354
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
Nakazawa M; Kyprianou N
J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
[TBL] [Abstract][Full Text] [Related]
15. Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer.
Huang H; Wang C; Liu F; Li HZ; Peng G; Gao X; Dong KQ; Wang HR; Kong DP; Qu M; Dai LH; Wang KJ; Zhou Z; Yang J; Yang ZY; Cheng YQ; Tian QQ; Liu D; Xu CL; Xu DF; Cui XG; Sun YH
Clin Cancer Res; 2018 Sep; 24(18):4612-4626. PubMed ID: 29691294
[No Abstract] [Full Text] [Related]
16. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.
Puhr M; Hoefer J; Schäfer G; Erb HH; Oh SJ; Klocker H; Heidegger I; Neuwirt H; Culig Z
Am J Pathol; 2012 Dec; 181(6):2188-201. PubMed ID: 23041061
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs and their potential for translation in prostate cancer.
DeVere White RW; Vinall RL; Tepper CG; Shi XB
Urol Oncol; 2009; 27(3):307-11. PubMed ID: 19414119
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs targeting prostate cancer stem cells.
Fang YX; Chang YL; Gao WQ
Exp Biol Med (Maywood); 2015 Aug; 240(8):1071-8. PubMed ID: 25966983
[TBL] [Abstract][Full Text] [Related]
19. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
[TBL] [Abstract][Full Text] [Related]
20. Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer.
Li P; Yang R; Gao WQ
Mol Cancer; 2014 Mar; 13():55. PubMed ID: 24618337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
